Brogaard Niels Juul, Hahn-Pedersen Julie Hviid, Gundgaard Jens, Polavieja Pepa, Bray Benjamin D, Chan Mei Sum, Hoang Men, Trepel Dominic
Novo Nordisk A/S, Søborg, Denmark.
Health Analytics, Lane Clark & Peacock LLP, London, UK.
Alzheimers Dement. 2025 Jun;21(6):e70163. doi: 10.1002/alz.70163.
We aimed to develop and externally validate a mapping to translate Mini-Mental State Examination (MMSE) scores to Clinical Dementia Rating scale Sum of Boxes (CDR-SB) scores in patients with Alzheimer's disease (AD).
We extended a previously published CDR-SB to MMSE mapping to include later stages of AD and validated it using the US National Alzheimer's Coordinating Centers (NACC) database. Calibration and discrimination metrics were evaluated, and the mapping was validated in clinically relevant subgroups of the AD population.
A linear MMSE to CDR-SB mapping ( demonstrated high goodness of fit and satisfied all validation metrics. The extended mapping performed well across subgroups, though calibration was less accurate for severe dementia patients.
This MMSE to CDR-SB MMSE mapping performed generally well though caution is needed when applying this mapping to people with severe AD dementia. It could be used to help contextualize outcomes in AD clinical trials and real-world health research studies.
We developed a mapping between the CDR-SB and MMSE instruments, by obtaining the optimal functional form of a mapping previously published using data from the Alzheimer's Disease Neuroimaging Initiative dataset and extending it to the full range of clinical severities for Alzheimer's disease. The resulting mapping was externally validated using 26,729 MMSE and CDR-SB pairs from participants recruited to the US National Alzheimer's Coordinating Centers database. The selected model satisfied the pre-specified selection criteria and the extended mapping demonstrated good performance, especially in the earlier clinical stages. However, caution is advised when inferring mapped scores in more severe dementia. The extension and subsequent validation of the mapping can support the translation of AD severity assessments between datasets using CDR-SB and MMSE, bridging a common information gap between clinical trials, real-world evidence studies, and clinical practice.
我们旨在开发并进行外部验证一种映射关系,以将阿尔茨海默病(AD)患者的简易精神状态检查表(MMSE)评分转换为临床痴呆评定量表总和(CDR-SB)评分。
我们扩展了先前发表的从CDR-SB到MMSE的映射关系,以纳入AD的后期阶段,并使用美国国家阿尔茨海默病协调中心(NACC)数据库对其进行验证。评估了校准和鉴别指标,并在AD人群的临床相关亚组中对该映射关系进行了验证。
从MMSE到CDR-SB的线性映射关系( 显示出良好的拟合优度,并满足所有验证指标。扩展后的映射关系在各亚组中表现良好,尽管对于重度痴呆患者,校准的准确性较低。
这种从MMSE到CDR-SB的映射关系总体表现良好,但在将此映射关系应用于重度AD痴呆患者时需要谨慎。它可用于帮助在AD临床试验和真实世界健康研究中对结果进行背景化。
我们通过使用阿尔茨海默病神经影像倡议数据集的数据获得先前发表的映射关系的最佳功能形式,并将其扩展到阿尔茨海默病的整个临床严重程度范围,从而开发了CDR-SB和MMSE工具之间的映射关系。使用从美国国家阿尔茨海默病协调中心数据库招募的参与者的26,729对MMSE和CDR-SB对,对所得映射关系进行了外部验证。所选模型满足预先指定的选择标准,扩展后的映射关系表现良好,尤其是在临床早期阶段。然而,在推断更严重痴呆中的映射评分时建议谨慎。该映射关系的扩展及后续验证可支持使用CDR-SB和MMSE在数据集之间转换AD严重程度评估,弥合临床试验、真实世界证据研究和临床实践之间常见的信息差距。